5-alpha-reductase type 2 (SRD5A2)
5-alpha-reductase turns testosterone into the more potent dihydrotestosterone inside the prostate; finasteride and dutasteride block it, and two large trials showed they cut prostate cancer diagnoses by about a quarter while raising concern about high-grade tumours. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
A membrane enzyme of the endoplasmic reticulum in prostate, genital skin and hair follicles; it is NADPH-dependent and genetic loss causes a disorder of sex development.
- Prostate epithelium and stroma
- Castration-resistant prostate cancer cells making their own androgens
External identifiers
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →No product in the corpus is aimed at this target yet.
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Literature
Preprints →Query for this target: (TITLE:"5-alpha-reductase type 2" OR ABSTRACT:"5-alpha-reductase type 2" OR TITLE:"SRD5A2" OR ABSTRACT:"SRD5A2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about 5-alpha-reductase type 2 (SRD5A2), not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/srd5a2.json. Licence CC BY-NC 4.0.